Catalog NumberHG8000280
CAS Number8000-28-0
CategoryNatural surfactants
Lavandula angustifolia Essential Oil Promotes Proregenerative Cytokine and VEGF Responses in Keratinocytes
Miastkowska, Małgorzata, et al. Molecules 26.9 (2021): 2458.
Lavandula angustifolia essential oil (lavender oil) was investigated for its proinflammatory and proregenerative effects on human keratinocytes, relevant to its traditional use in wound healing and skin inflammation.
Experimental Protocol: A commercial Provence oil (LO-C) and an in-house Polish steam-distilled oil (LO-SM, 250 g dried flowers, 2 h distillation) were analysed by GC/MS. HaCaT keratinocytes and monocyte-derived macrophages (hMDM) were treated with 0.1% oil for 4 or 24 h, with or without Escherichia coli LPS (HaCaT 5 µg/mL; hMDM 100 ng/mL); cytokine gene expression was measured by real-time PCR, secreted protein by ELISA, and cytotoxicity by the MTT assay.
Performance Evaluation: LO-SM contained less linalool (23.2 vs 40.2%) but far more lavandulyl acetate (23.2 vs 5.5%) than LO-C. Lavender oil induced IL-8 nearly fourfold and IL-6, VEGF and IL-1β about twofold, with VEGF reaching ~500 pg/mL. Under LPS co-stimulation, VEGF-A rose 15-fold (LO-SM) and 23-fold (LO-C), IL-8 reached 600/300 pg/mL, and LO-SM reduced macrophage TNF-α and IL-6 by ~50%, indicating enhanced wound-healing signaling.
Lavandula angustifolia Essential Oil Combinations Show Synergistic and Additive Antimicrobial Activity
de Rapper, Stephanie, et al. Evidence-Based Complementary and Alternative Medicine 2013.1 (2013): 852049.
Lavandula angustifolia essential oil (lavender oil) was assessed in combination with 45 other aroma-therapeutic oils to establish interactive antimicrobial properties supporting aromatherapy blending.
Experimental Protocol: Oil compositions were confirmed by GC-MS with flame ionization detection (HP-Innowax column). Individual and 1:1 combined minimum inhibitory concentrations (MICs) were determined by the microdilution assay in 96-well plates, using oils diluted in acetone and serially tested from 8 to 0.0625 mg/mL against Staphylococcus aureus ATCC 6538, Pseudomonas aeruginosa ATCC 27858 and Candida albicans ATCC 10231 (inoculum ~1 × 106 CFU/mL, with INT as viability indicator). Fractional inhibitory concentration indices (ΣFIC) were calculated, and isobolograms were constructed across nine ratios (9:1 to 1:9) for promising pairs.
Performance Evaluation: Lavender oil alone predominantly gave MICs of 2.00 mg/mL (Klebsiella pneumoniae 1.50, Candida tropicalis 0.75, C. albicans 3.00 mg/mL). In 1:1 blends, 26.7% of combinations were synergistic, 48.9% additive, 23.7% non-interactive and only 0.7% antagonistic (Cymbopogon citratus, ΣFIC 6.67). Lavender with Cinnamomum zeylanicum (C. albicans) and with Citrus sinensis (S. aureus) gave the most favorable interactions.
Lavandula angustifolia Essential Oil Reduces Acute Inflammatory Edema, MPO and Nitric Oxide in Mice
Cardia, Gabriel Fernando Esteves, et al. Evidence-Based Complementary and Alternative Medicine 2018.1 (2018): 1413940.
Lavandula angustifolia essential oil (LEO) was evaluated for anti-inflammatory activity in acute inflammation models, extending its reported antioxidant and antimicrobial properties.
Experimental Protocol: LEO was obtained by steam distillation (3 h) and characterized by GC-MS and NMR. Swiss mice received topical LEO (0.125-2.5 mg/ear) in a croton oil-induced ear edema model, or oral LEO (50-250 mg/kg) in carrageenan- and dextran-induced paw edema models; reference drugs were dexamethasone (0.1 mg/ear), indomethacin (5 mg/kg), celecoxib (10 mg/kg) and promethazine (10 mg/kg). Edema, myeloperoxidase (MPO) activity and nitric oxide (nitrite) were quantified, with leukocyte viability (MTT) and chemotaxis tested in vitro.
Performance Evaluation: LEO contained 1,8-cineole (39.83%), borneol (22.63%) and camphor (22.12%). Topical LEO (0.25 mg/ear) reduced croton-oil ear edema by 59.6%, MPO activity by 62.5% and nitrite by up to 82.3%. Orally, 100 mg/kg reduced carrageenan paw edema by up to 65.7% and MPO by 50.3%, while 75-100 mg/kg reduced dextran-induced edema and MPO (57.4-62%). Notably, a high topical dose (2.5 mg/ear) was irritant, increasing edema.